The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Angiotensin receptor blockers as tentative SARS‐CoV‐2 therapeutics
Open accessAbstract
At the time of writing this commentary (February 2020), the coronavirus COVID‐19 epidemic has already resulted in more fatalities compared with the SARS and MERS coronavirus epidemics combined. Therapeutics that may assist to contain its rapid spread and reduce its high mortality rates are urgently needed. Developing vaccines against the SARS‐CoV‐2 virus may take many months. Moreover, vaccines based on viral‐encoded peptides may not be effective against future coronavirus epidemics, as virus mutations could make them futile. Indeed, new Influenza virus strains emerge every year, requiring new immunizations. A tentative suggestion based on existing therapeutics, which would likely be resistant to new coronavirus mutations, is to use available angiotensin receptor 1 (AT1R) blockers, such as losartan, as therapeutics for reducing the aggressiveness and mortality from SARS‐CoV‐2 virus infections. This idea is based on observations that the angiotensin‐converting enzyme 2 (ACE2) very likely serves as the binding site for SARS‐CoV‐2, the strain implicated in the current COVID‐19 epidemic, similarly to strain SARS‐CoV implicated in the 2002–2003 SARS epidemic. This commentary elaborates on the idea of considering AT1R blockers as tentative treatment for SARS‐CoV‐2 infections, and proposes a research direction based on datamining of clinical patient records for assessing its feasibility.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., Wang, W., Song, H., Huang, B., Zhu, N., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30251-8 · Cited by 11,907
Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
Li, W., Moore, M. J., Vasilieva, N., Sui, J., Wong, S. K., Berne, M. A., Somasundaran, M., Sullivan, J. L., Luzuriaga, K., Greenough, T. C., et al. (2003) · Nature · doi:10.1038/nature02145 · Cited by 5,923
Wan, Y., Shang, J., Graham, R., Baric, R. S., & Li, F. (2020) · Journal of Virology · doi:10.1128/jvi.00127-20 · Cited by 4,341
SARS and MERS: recent insights into emerging coronaviruses
de Wit, E., van Doremalen, N., Falzarano, D., & Munster, V. J. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.81 · Cited by 3,510
A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury
Kuba, K., Imai, Y., Rao, S., Gao, H., Guo, F., Guan, B., Huan, Y., Yang, P., Zhang, Y., Deng, W., et al. (2005) · Nature Medicine · doi:10.1038/nm1267 · Cited by 3,445
Gao, J., Tian, Z., & Yang, X. (2020) · BioScience Trends · doi:10.5582/bst.2020.01047 · Cited by 2,590
Angiotensin-converting enzyme 2 protects from severe acute lung failure
Imai, Y., Kuba, K., Rao, S., Huan, Y., Guo, F., Guan, B., Yang, P., Sarao, R., Wada, T., Leong-Poi, H., et al. (2005) · Nature · doi:10.1038/nature03712 · Cited by 2,453
Angiotensin-(1–7) is an endogenous ligand for the G protein-coupled receptor Mas
Santos, R. A. S., e Silva, A. C. S., Maric, C., Silva, D. M. R., Machado, R. P., de Buhr, I., Heringer-Walther, S., Pinheiro, S. V. B., Lopes, M. T., Bader, M., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1432869100 · Cited by 1,801
Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor
Ge, X.-Y., Li, J.-L., Yang, X.-L., Chmura, A. A., Zhu, G., Epstein, J. H., Mazet, J. K., Hu, B., Zhang, W., Peng, C., et al. (2013) · Nature · doi:10.1038/nature12711 · Cited by 1,778
Therapeutic options for the 2019 novel coronavirus (2019-nCoV)
Li, G., & De Clercq, E. (2020) · Nature Reviews Drug Discovery · doi:10.1038/d41573-020-00016-0 · Cited by 1,729
Potential interventions for novel coronavirus in China: A systematic review
Zhang, L., & Liu, Y. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25707 · Cited by 1,348
Structure analysis of the receptor binding of 2019-nCoV
Chen, Y., Guo, Y., Pan, Y., & Zhao, Z. J. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.02.071 · Cited by 806
Mahase, E. (2020) · BMJ · doi:10.1136/bmj.m641 · Cited by 720
2019 Novel coronavirus: where we are and what we know
Cheng, Z. J., & Shan, J. (2020) · Infection · doi:10.1007/s15010-020-01401-y · Cited by 629
Luo, H., Tang, Q.-L., Shang, Y.-X., Liang, S.-B., Yang, M., Robinson, N., & Liu, J.-P. (2020) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-020-3192-6 · Cited by 613
Ishiyama, Y., Gallagher, P. E., Averill, D. B., Tallant, E. A., Brosnihan, K. B., & Ferrario, C. M. (2004) · Hypertension · doi:10.1161/01.hyp.0000124667.34652.1a · Cited by 564
Tseng, C.-T., Sbrana, E., Iwata-Yoshikawa, N., Newman, P. C., Garron, T., Atmar, R. L., Peters, C. J., & Couch, R. B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035421 · Cited by 561
ACE2: from vasopeptidase to SARS virus receptor
Turner, A. J., Hiscox, J. A., & Hooper, N. M. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.04.001 · Cited by 517
Patel, A., Jernigan, D. B., 2019-nCoV CDC Response Team, 2019-nCoV CDC Response Team, Abdirizak, F., Abedi, G., Aggarwal, S., Albina, D., Allen, E., Andersen, L., et al. (2020) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6905e1 · Cited by 449
Cardiovascular complications of severe acute respiratory syndrome
Yu, C.-M., Wong, R. S.-M., Wu, E. B., Kong, S.-L., Wong, J., Yip, G. W.-K., Soo, Y. O. Y., Chiu, M. L. S., Chan, Y.-S., Hui, D., et al. (2006) · Postgraduate Medical Journal · doi:10.1136/pgmj.2005.037515 · Cited by 345
Repeated annual influenza vaccination and vaccine effectiveness: review of evidence
Belongia, E. A., Skowronski, D. M., McLean, H. Q., Chambers, C., Sundaram, M. E., & De Serres, G. (2017) · Expert Review of Vaccines · doi:10.1080/14760584.2017.1334554 · Cited by 281
Furuhashi, M., Moniwa, N., Mita, T., Fuseya, T., Ishimura, S., Ohno, K., Shibata, S., Tanaka, M., Watanabe, Y., Akasaka, H., et al. (2015) · American Journal of Hypertension · doi:10.1093/ajh/hpu086 · Cited by 263
[Inhibitors of RAS Might Be a Good Choice for the Therapy of COVID-19 Pneumonia].
Sun, M. L., Yang, J. M., Sun, Y., & Su, G. (2020) · PubMed · doi:10.3760/cma.j.issn.1001-0939.2020.0014 · Cited by 228
Michel, N., Allespach, I., Venzke, S., Fackler, O. T., & Keppler, O. T. (2005) · Current Biology · doi:10.1016/j.cub.2005.02.058 · Cited by 222
A model of the ACE2 structure and function as a SARS-CoV receptor
Prabakaran, P., Xiao, X., & Dimitrov, D. S. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.12.081 · Cited by 209
Patel, A., & Jernigan, D. B. (2020) · American Journal of Transplantation · doi:10.1111/ajt.15805 · Cited by 197
Structure-Based Discovery of a Novel Angiotensin-Converting Enzyme 2 Inhibitor
Huentelman, M. J., Zubcevic, J., Hernández Prada, J. A., Xiao, X., Dimitrov, D. S., Raizada, M. K., & Ostrov, D. A. (2004) · Hypertension · doi:10.1161/01.hyp.0000146120.29648.36 · Cited by 188
Beigel, J. H., Nam, H. H., Adams, P. L., Krafft, A., Ince, W. L., El-Kamary, S. S., & Sims, A. C. (2019) · Antiviral Research · doi:10.1016/j.antiviral.2019.04.006 · Cited by 169
The Secret Life of ACE2 as a Receptor for the SARS Virus
Dimitrov, D. S. (2003) · Cell · doi:10.1016/s0092-8674(03)00976-0 · Cited by 141
McIntyre, M., Caffe, S. E., Michalak, R., & Reid, J. L. (1997) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(97)82002-5 · Cited by 112
Klimas, J., Olvedy, M., Ochodnicka‐Mackovicova, K., Kružliak, P., Čačányiová, S., Kristek, F., Křenek, P., & Ochodnický, P. (2015) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12573 · Cited by 111
Telmisartan: a review of its pharmacodynamic and pharmacokinetic properties
Deppe, S., Böger, R. H., Weiß, J., & Benndorf, R. A. (2010) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2010.494597 · Cited by 84
Smyth, L. J., Cañadas‐Garre, M., Cappa, R., Maxwell, A. P., & McKnight, A. J. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-026777 · Cited by 62
Cited by
Extrapulmonary manifestations of COVID-19
Gupta, A., Madhavan, M. V., Sehgal, K., Nair, N., Mahajan, S., Sehrawat, T. S., Bikdeli, B., Ahluwalia, N., Ausiello, J. C., Wan, E. Y., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0968-3 · Cited by 3,185
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review
Sanders, J. M., Monogue, M. L., Jodlowski, T. Z., & Cutrell, J. B. (2020) · JAMA · doi:10.1001/jama.2020.6019 · Cited by 2,347
Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19
Vaduganathan, M., Vardeny, O., Michel, T., McMurray, J. J. V., Pfeffer, M. A., & Solomon, S. D. (2020) · New England Journal of Medicine · doi:10.1056/nejmsr2005760 · Cited by 2,101
Driggin, E., Madhavan, M. V., Bikdeli, B., Chuich, T., Laracy, J., Biondi-Zoccai, G., Brown, T. S., Der Nigoghossian, C., Zidar, D. A., Haythe, J., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.03.031 · Cited by 2,017
COVID‐19 diagnosis and management: a comprehensive review
Pascarella, G., Strumia, A., Piliego, C., Bruno, F., Del Buono, R., Costa, F., Scarlata, S., & Agrò, F. E. (2020) · Journal of Internal Medicine · doi:10.1111/joim.13091 · Cited by 1,369
Metadata
- Authors
- Gurwitz, D.
- Venue
- Drug Development Research
- Publisher
- Wiley
- Published
- 2020-03-04
- Volume
- 81
- Issue
- 5
- Pages
- 537-540
- ISSN
- 0272-4391 (ISSN-L)
- 1098-2299
- OpenAlex
- W3009723094
- Cited by
- 802
- References
- 33
- FWCI
- 23.24
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.